Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

Kiadis Pharma Terug naar discussie overzicht

Januari 2019. De goedkeuring komt eraan in H1-2019 !!!

1.504 Posts
Pagina: «« 1 2 3 4 5 6 ... 76 »» | Laatste | Omlaag ↓
  1. kmmr 2 januari 2019 11:34

    • kmmr

      Lid sinds: 16 mrt 2018

      Laatste bezoek: 25 jul 2024

    • Aanbevelingen

      Ontvangen: 77

      Gegeven: 2

    •    Aantal posts: 725

    quote:

    Piet Particulier schreef op 2 januari 2019 11:32:

    Veel kopers ineens, dit gaat interessant worden.

    8 einde van de dag?!
    Ik ga eigenlijk uit van een wat hogere koers. Binnen een paar weken zou er zo maar een PB kunnen zijn dat de vragen zijn beantwoord.
  6. Teti 2 januari 2019 11:50

    • Teti

      Lid sinds: 20 nov 2017

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 89

      Gegeven: 23

    •    Aantal posts: 110

    Zouden ze dit doen als ze niet 100% overtuigd zijn van goedkeuring?
    Dit is voor mij duidelijk.
    Atir gaat er komen......

    As a Key Account Manager Germany at Kiadis Pharma, you will be responsible for;

    Leading the launch preparation then launching ATIR101 in Germany,
  7. Tommie_Hilfiger 2 januari 2019 11:52

    • Tommie_Hilfiger

      Lid sinds: 31 jan 2014

      Laatste bezoek: 05 jun 2024

    • Aanbevelingen

      Ontvangen: 52

      Gegeven: 8

    •    Aantal posts: 604

    Net voor vorig weekend geposte vacature: "Leading the launch preparation then launching ATIR101 in Germany"

    ^

    Kiadis Pharma is a biopharmaceutical company based in Amsterdam, The Netherlands.

    We focus on the treatment of blood cancers and inherited blood disorders aiming to make bone marrow transplantations, a risky procedure that is often the last hope for patients, safer and more efficient. This means we have a passionate team that is dedicated to make a huge difference for patients.

    If you are up to the challenge and would like to be part of our team, we are currently looking for a driven Key Account Manager Germany.
    As a Key Account Manager Germany at Kiadis Pharma, you will be responsible for;

    Leading the launch preparation then launching ATIR101 in Germany, alongside MSL colleague(s) from a commercial / customer facing perspective across key transplantation centres/ customers. Delivering against commercial targets that are set and acting as the voice of the German customer back into the above country commercial team.
    Areas of full responsibility;

    Being the primary commercial customer facing representative of Kiadis in Germany/ across agreed key accounts.
    Leading the local account planning process – account identification, prioritisation, key customer mapping and building of cross functional account plans.
    Set-up and execution of the wider Germany commercial plan – congresses, webinars, other key customer meetings.
    Leading execution of the customer facing account / activity plans to drive usage/ sales of ATIR101 through the launch phase in Germany.
    Linking with the European commercial/ marketing teams to provide customer insight / seek support and to define the design/ set-up of the Kiadis service capability.
    Areas of Support;
    Builds/ agrees local Key Account Plans with the partner MSL(s).
    Feeds relevant customer feedback/ objections/ insight into the European commercial team and seeks European level customer facing support as needed.
    Seeks additional and relevant internal and external training/ learnings opportunities to continue to develop expertise/ knowledge of the disease and therapy area.
    Over-all activities;
    Identify the high priority/ high potential transplantation centres to focus on for launch.
    Identify/ map out the key customers across the key centres that should be targeted for launch through initial introductory meetings.
    Build hospital/ centre level key account plans across all key stakeholders to prepare for launch.
    Own the launch/ sales line of ATIR101 in-line with agreed brand strategy across key transplantation centres – acting as the primary point contact from Kiadis across the end to end patient/ customer journey – and by executing the agreed customer call/ account plans in-line with the defined KPIs.
    Help set-up then leverage the wider / central Kiadis service support capability to support customers in the end to end process from patient and donor identification to longer term patient management.
    Set-up/ execute the account/ Germany specific wider commercial plan – speaker meetings, local congresses, local webinars etc.
    The ideal candidate / Role Requirements;

    You have a University Degree level.

    You have a significant (8+ years) sales and senior key account management experience in specialty/ hospital customer facing roles, including a track record of working effectively with specialists/ in a secondary or tertiary care setting.

    You are excellent in commercial project management.

    You are self-sufficient and driven, but also a strong team player with the ability to work cross-functionally as part of a multi-disciplinary / matrix team – in particular with in field medical colleagues.

    You have relevant experience of leading teams and creating sales plans from the ground up.

    You have a background ideally in Oncology/ Haematology and-or cell (gene) therapy.

    We offer

    A challenging position in an innovative, fast growing biotechnology company.

    You will be working in a fast-paced dynamic environment which provides the opportunity to make your own mark within the organization and build our ambitious HR team. You will be rewarded a competitive remuneration package, the opportunity for personal development and are able to contribute to make a huge difference for patients worldwide.

    For further information, please contact us by e-mail at recruitment@kiadis.com.

    If you're interested in the position please apply directly through the application button.
  8. Tommie_Hilfiger 2 januari 2019 11:53

    • Tommie_Hilfiger

      Lid sinds: 31 jan 2014

      Laatste bezoek: 05 jun 2024

    • Aanbevelingen

      Ontvangen: 52

      Gegeven: 8

    •    Aantal posts: 604

    Nog een 2e werd gepost net voor vorig weekend: "Defining and owning the ATIR101 brand strategy for launch across Europe."

    ^

    Kiadis Pharma is a biopharmaceutical company based in Amsterdam, The Netherlands.

    We focus on the treatment of blood cancers and inherited blood disorders aiming to make bone marrow transplantations, a risky procedure that is often the last hope for patients, safer and more efficient. This means we have a passionate team that is dedicated to make a huge difference for patients.

    If you are up to the challenge and would like to be part of our team, we are currently looking for a driven Head of Marketing

    As our Head of Marketing you are leading the European marketing effort to/ through the launch of ATIR101 – from concept to execution; brand strategy, positioning, essence, look and feel/ creative concept, commercial story flow/ messaging and ultimately the cross-channel / digital marketing approach and materials for training and launch.

    As a Head of Marketing at Kiadis Pharma, you will be responsible for;

    Defining and owning the ATIR101 brand strategy for launch across Europe.
    Defining and owning the positioning, essence, look and feel/ creative concept, commercial story flow/ messaging.
    All core marketing deliverables / content needed for launch – across all channels – on-line and offline – including materials / infrastructure needed for patient engagement/ support.
    Set-up and ownership of the external / commercial engagement plan – congresses, webinars, KOLs as relevant.
    All commercial training materials / training of customer facing teams needed for launch.
    Pre and post launch KPIs and targets.
    Leading the work across key functions – including Account Managers/ Head of Account Managers to define and agree the brand strategy for launch.
    Lead the process to choose an external marketing / comms agency to partner with for launch then work with/ manage the agency.
    Defining the marketing channel strategy/ mix for/ post launch and then lead the development of all associated content/ materials.
    Defining the training approach for the commercial Key Account Managers – and lead the preparation of associated materials.
    Preparing the content to be used at external congresses for commercial activities/ booths.

    The ideal candidate / Role Requirements;

    You have a University Degree level or higher, ideally with marketing accreditation.
    You have significant (8+ years) in and above country experience of leading strategic and operational digital/ multi-channel marketing work in Europe and/ or globally and in particular experience in leading product launches (from conception to post launch).
    You are strong in project and vendor management
    Needless to say you are astrong team player and leader with an ability to work cross-functionally as part of a multi-disciplinary / matrix team and to lead direct teams/ reports.
    Ideally experience in Oncology/ Haematology, cell (gene) therapy, speciality medicines or other

    We offer

    A challenging position in an innovative, fast growing biotechnology company.

    You will be working in a fast-paced dynamic environment which provides the opportunity to make your own mark within the organization and build our ambitious HR team. You will be rewarded a competitive remuneration package, the opportunity for personal development and are able to contribute to make a huge difference for patients worldwide.

    For further information, please contact us by e-mail at recruitment@kiadis.com.

    If you're interested in the position please apply directly through the application button.
  10. Cerazeen 2 januari 2019 12:06

    • Cerazeen

      Lid sinds: 18 jul 2018

      Laatste bezoek: 16 jan 2025

    • Aanbevelingen

      Ontvangen: 17

      Gegeven: 4

    •    Aantal posts: 160

    Aan iedereen op het forum mijn beste wensen voor een vreugdevol en succesrijk 2019 !
    Ik vermoed dat het weer een woelig jaar wordt maar maakt dit het nu net niet spannend...
    Kiadis sowieso één van mijn favorieten net als Oxurion voor beiden moeten we echter (veel) geduld hebben ...

  12. kmmr 2 januari 2019 12:07

    • kmmr

      Lid sinds: 16 mrt 2018

      Laatste bezoek: 25 jul 2024

    • Aanbevelingen

      Ontvangen: 77

      Gegeven: 2

    •    Aantal posts: 725

    Zeker weten, en ik verwacht de 9 ook snel te zien, en dan is het hek van de dam.
  14. kmmr 2 januari 2019 12:16

    • kmmr

      Lid sinds: 16 mrt 2018

      Laatste bezoek: 25 jul 2024

    • Aanbevelingen

      Ontvangen: 77

      Gegeven: 2

    •    Aantal posts: 725

    quote:

    Cerazeen schreef op 2 januari 2019 12:09:

    niet euforisch worden ivm deze personeelsadvertenties...
    Dat was ik al. Dit is alleen weer een bevestiging
  15. [verwijderd] 2 januari 2019 12:19

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Lijkt een goede ontwikkeling, weer eens een bewijs dat Kiadis niet mee beweegt op het sentiment van de dag.

    Toch stap ik nog niet in, wil eerst een koers zien van tenminste € 10,00 gezien de ervaringen van de afgelopen tijd
  20. Windkracht 2 januari 2019 12:29

    • Windkracht

      Lid sinds: 18 jan 2008

      Laatste bezoek: 15 nov 2024

    • Aanbevelingen

      Ontvangen: 261

      Gegeven: 78

    •    Aantal posts: 2.319

    Dit gaat mooi zo, die EUR 8,50-9,00 die ik einde week verwachtte moet makkelijk haalbaar zijn zo! Ruim een week geleden weer vol in Kiadis gegaan, vooralsnog mooie timing.
  21. [verwijderd] 2 januari 2019 12:33

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Windkracht schreef op 2 januari 2019 12:29:

    Dit gaat mooi zo, die EUR 8,50-9,00 die ik einde week verwachtte moet makkelijk haalbaar zijn zo! Ruim een week geleden weer vol in Kiadis gegaan, vooralsnog mooie timing.
    Gefeliciteerd, dat maakt weer wat goed van de verliezen die je afgelopen tijd met het aandeel hebt geleden. Komt goed
1.504 Posts
Pagina: «« 1 2 3 4 5 6 ... 76 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.482
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.206
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.528
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.651
Aedifica 3 901
Aegon 3.258 322.664
AFC Ajax 538 7.086
Affimed NV 2 6.288
ageas 5.844 109.885
Agfa-Gevaert 14 2.048
Ahold 3.538 74.294
Air France - KLM 1.025 34.999
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.333
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.813
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.752
AMG 971 133.100
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 485
Antonov 22.632 153.605
Aperam 92 14.936
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.582
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.716
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.082
ASML 1.766 106.069
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 470
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.610
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390